title: Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy.
abstract: OBJECTIVE
  Efficacy of intermittent palonosetron dosing in patients undergoing multiple-day, high-dose chemotherapy (HDC) was investigated.
  
  
  METHODS
  Fifty-eight patients received palonosetron (0.25 mg intravenous [iv.]) every other day plus daily dexamethasone (8 mg iv. twice daily) dosing. The primary end point was complete control (CC; no emesis, no rescue anti-emetics, and no more than mild nausea) in the overall acute-period (until 24 h after chemotherapy completion).
  
  
  RESULTS
  Acute-period CC occurred in 81% and 50% of patients receiving palonosetron and ondansetron (historical control cohort), respectively. Palonosetron (odds ratio [OR]: 4.37; p = 0.001) and a longer duration of HDC regimen (OR: 3.47; p = 0.011) independently predicted a better anti-emetic outcome.
  
  
  CONCLUSIONS
  Palonosetron every other day plus daily dexamethasone is an effective anti-emetic coverage in patients undergoing HDC.
authors.affiliation: Department of Medical Oncology, Fondazione IRCCS 'Istituto Nazionale Tumori', Milan, Italy.
authors.forename: Aurora
authors.initials: A
authors.lastname: Mirabile
authors.forename: Luigi
authors.initials: L
authors.lastname: Celio
authors.forename: Michele
authors.initials: M
authors.lastname: Magni
authors.forename: Erminio
authors.initials: E
authors.lastname: Bonizzoni
authors.forename: Alessandro Massimo
authors.initials: AM
authors.lastname: Gianni
authors.forename: Massimo
authors.initials: M
authors.lastname: Di Nicola
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D004359:Drug Therapy, Combination; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D007546:Isoquinolines / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077924:Palonosetron; D011812:Quinuclidines / Q000008:administration & dosage* / Q000009:adverse effects; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D007546:Isoquinolines; D011812:Quinuclidines; D000077924:Palonosetron; D003907:Dexamethasone
keywords: CINV; dexamethasone; high-dose chemotherapy; nausea; vomiting